One of the health highlights mentioned in this update compiled by editors outlines the conclusions from a recent ISMP QuarterWatch report that examined many unanswered questions about the safety and effectiveness of pimavanserin (Nuplazid), a drug used to treat psychosis in Parkinson's patients, and called for stronger warnings on its label.
For the full text, visit U.S. News & World Report online.
More News
Reflecting on the 20-year anniversary of the watershed Institute of Medicine report To Err Is Human, ISMP has published a “top ten” list of the most persistent medication errors and safety issues covered in its newsletter in 2019.
As state legalization of medical marijuana sales spreads, issues have arisen with confusing product labeling that has led to errors.
ECRI Institute and the Institute for Safe Medication Practices (ISMP) announce the successful completion of their plans to join forces. Effective today, ISMP is an ECRI Institute affiliate. By joining together, the two patient safety leaders have created one of the largest healthcare quality and